



Schrödinger to Present at H.C. Wainwright BioConnect Conference

January 5, 2022

NEW YORK--(BUSINESS WIRE)--Jan. 5, 2022-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Conference. The pre-recorded presentation will be available on Monday, January 10, 2022, at 11:00 a.m. ET.

The "on demand" webcast can be accessed under "News & Events" in the investors section of Schrödinger's website, <https://ir.schrodinger.com/news-and-events/event-calendar> and will be archived for approximately seven days.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger's multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 500 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on [LinkedIn](#) and [Twitter](#), or visit our blog, Extrapolations.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220105005453/en/): <https://www.businesswire.com/news/home/20220105005453/en/>

Jaren Irene Madden
Schrödinger, Inc.
jaren.madden@schrodinger.com
617-286-6264

Tracy Lessor
Schrödinger, Inc.
tracy.lessor@schrodinger.com
617-519-9827

Source: Schrödinger, Inc.